



# Pharmaids Pharmaceuticals Limited

PPL/BSE/Q3/187/15-16

Fax/Courier/Email

Date: 15/02/2016

To  
The Corporate Relation Department  
The Bombay Stock Exchange Ltd.  
Floor 25, P J Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sir

Sub: Outcome of Board Meeting

Ref: Regulation 33 of SEBI (LODR) Regulations, 2015  
Scrip Code - 524572


The Board of Directors of the Company at their meeting held on 15<sup>th</sup> February, 2015 have approved the Unaudited Financial Results for the quarter / nine months ended 31<sup>st</sup> December, 2015. A copy of the same is enclosed.

Please also find enclosed the Limited Review Report for the quarter ended 31<sup>st</sup> December, 2015 as approved by the Board of Directors of the Company.

Kindly acknowledge the receipt of the same.

Thanking You.

Yours faithfully,  
for Pharmaids Pharmaceuticals Limited

  
Dr. Ghisulal Jain  
Chairman & Managing Director  
Encl: As above

---

CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095. TELANGANA (INDIA)  
Ph : 6559 9809, Tele Fax : 040-2756 2126. email : mailpharmaids@yahoo.co.in, Website : www.pharmaids.com  
Unit : Survey No. 533, (V) Kondamadugu, (M) Bibi Nagar, District Nalgonda (Telangana). Phone : +91-92470 58492



# Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

## EXTRACT OF STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31st DECEMBER, 2015

### PART - I

S. No	Particulars	(Amt in lakhs)					
		QUARTER ENDED			NINE MONTHS PERIOD ENDED		YEAR ENDED
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	30.12.2014	31.03.2015
		Un-audited			Un- Audited		Audited
1	Income from Operations						
	(a) Net Sales/Income from operations	52.75	31.66	50.61	141.90	90.46	173.04
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations	52.75	31.66	50.61	141.90	90.46	173.04
2	Expenses						
	a. Consumption of raw materials	12.96	5.06	3.02	23.13	4.46	0.00
	b. Purchases of stock-in-trade	22.93	21.18	39.37	65.72	46.39	104.19
	c. increase/decrease in stock in trade and WIP	(5.01)	(4.91)	(15.00)	(4.35)	0.94	(0.50)
	d. Power & Fuel	0.00	0.00	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00	0.00
	f. Employees Cost	5.35	6.07	5.65	16.60	9.31	18.20
	g. Depreciation	2.52	2.52	1.68	7.46	3.35	13.71
	h. Other expenditure	35.28	11.57	14.09	59.28	34.47	60.31
	Total	74.03	41.49	48.81	167.84	98.93	195.91
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other income, finance costs and Exceptional Items (1-2)	(21.28)	(9.83)	1.80	(25.94)	(8.47)	(22.87)
4	Other Income	0.06	4.50	0.04	4.56	12.53	12.42
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items	(21.22)	(5.33)	1.84	(21.38)	4.06	(10.45)
6	Finance Cost	1.00	0.81	0.00	1.84	0.00	0.15
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	(22.22)	(6.14)	1.84	(23.22)	4.06	(10.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax	(22.22)	(6.14)	1.84	(23.22)	4.06	(10.60)
10	Tax expense						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	4.05
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+) / Loss (-) from ordinary activities after tax	(22.22)	(6.14)	1.84	(23.22)	4.06	(6.55)
12	Extraordinary items (net of tax expense Rs. Nil)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit (+) / Loss (-) for the period	(22.22)	(6.14)	1.84	(23.22)	4.06	(6.55)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.94	9.94	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extra- ordinary items - not annualised)						
	a) Basic	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)
	b) Diluted	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)
17	Earnings Per Share (after extra- ordinary items - not annualised)						
	a) Basic	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)
	b) Diluted	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)

#### Notes:

- The above unaudited results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 15th Feb, 2016
- Figures for the previous Year/Quarter have been rearranged/regrouped wherever necessary and the statutory auditors have carried out a limited review of these results.
- The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard-17 on segment reporting issued by the ICAI
- Provisions for Income Tax and Deferred Tax will be made at the end of the Financial Year

PLACE : HYDERABAD  
DATE : 15.02.2016

For RAKESH S JAIN & ASSOCIATES  
CHARTERED ACCOUNTANTS

For PHARMAIDS PHARMACEUTICALS LIMITED  
Dr. Ghisulal Jain  
Managing Director

(B. RAMESH KUMAR)  
PARTNER

# Pharmaids Pharmaceuticals Limited

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095.

Email: mail@pharmaids.com, pharmaids.co.in, Website: www.pharmaids.com

CIN No. L52520TG1989PLC009679

## EXTRACT OF STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31st DECEMBER, 2015

### PART - I

S. No	Particulars	QUARTER ENDED			NINE MONTHS PERIOD ENDED		(Amt in lakhs)
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	30.12.2014	YEAR ENDED
		Un-audited			Un-Audited		Audited
1	Income from Operations						
	(a) Net Sales/Income from operations	52.75	31.66	50.61	141.90	90.46	173.04
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations	52.75	31.66	50.61	141.90	90.46	173.04
2	Expenses						
	a. Consumption of raw materials	12.96	5.06	3.02	23.13	4.46	0.00
	b. Purchases of stock-in-trade	22.93	21.18	39.37	65.72	46.39	104.19
	c. Increase/decrease in stock in trade and WIP	(5.01)	(4.91)	(15.00)	(4.35)	0.84	(0.50)
	d. Power & Fuel	0.00	0.00	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00	0.00
	f. Employees Cost	5.35	6.07	5.65	16.60	9.31	18.20
	g. Depreciation	2.52	2.52	1.68	7.46	3.36	13.71
	h. Other expenditure	35.28	11.57	14.09	59.28	34.47	60.31
	Total	74.03	41.49	48.81	167.84	98.93	195.91
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other Income, finance costs and Exceptional Items (1-2)	(21.28)	(9.83)	1.80	(26.94)	(8.47)	(22.87)
4	Other Income	0.06	4.50	0.04	4.56	12.53	12.42
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items	(21.22)	(5.33)	1.84	(21.38)	4.06	(10.45)
6	Finance Cost	1.00	0.81	0.00	1.84	0.00	0.15
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	(22.22)	(6.14)	1.84	(23.22)	4.06	(10.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax	(22.22)	(6.14)	1.84	(23.22)	4.06	(10.60)
10	Tax expense						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	4.05
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+)/ Loss (-) from ordinary activities after tax	(22.22)	(6.14)	1.84	(23.22)	4.06	(6.55)
12	Extraordinary items (net of tax expense Rs.Nil)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit (+)/ Loss (-) for the period	(22.22)	(6.14)	1.84	(23.22)	4.06	(6.55)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.94	9.94	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extra-ordinary items - not annualised)						
	a) Basic	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)
	b) Diluted	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)
17	Earnings Per Share (after extra-ordinary items - not annualised)						
	a) Basic	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)
	b) Diluted	(0.65)	(0.18)	0.05	(0.68)	0.12	(0.19)

#### Notes:

- The above unaudited results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 15th Feb, 2016
- Figures for the previous Year/Quarter have been rearranged/regrouped wherever necessary and the statutory auditors have carried out a limited review of these results.
- The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard-17 on segment reporting issued by the ICAI
- Provisions for Income Tax and Deferred Tax will be made at the end of the Financial Year

For PHARMAIDS PHARMACEUTICALS LIMITED

Dr. Ghisulal Jain  
Managing Director

PLACE : HYDERABAD

DATE : 15.02.2016





**RAKESH S JAIN & ASSOCIATES**  
CHARTERED ACCOUNTANTS

14-6-191, Nagar Khana, Begum Bazar,  
HYDERABAD - 500 012. (A.P.) INDIA

E-mail : rsjainassociates@rediffmail.com  
Fax : 040-24617420  
Suresh Kumar Jain (Mob) : +91-9849025612  
B. Ramesh Kumar (Mob) : +91-9849025641

### LIMITED REVIEW REPORT

Date :

We have reviewed the accompanying statement of unaudited financial results of **M/S. PHARMAIDS PHARMACEUTICALS LIMITED** for the Quarter ended 31<sup>st</sup> December, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rakesh S Jain & Associates  
Chartered Accountants  
Firm Registration No. 010129S

Date: 15.02.2016  
Place: Hyderabad.

  
(B. Ramesh Kumar)  
Partner  
M. No. 200304  
